• News
  • Stock Screener
  • Small Caps
  • Guru Portfolios
  • Review
  • News
  • Stock Screener
  • Small Caps
  • Guru Portfolios
  • Review
  • X (Twitter)
  • LinkedIn
Stock Screener·India·Healthcare·MEDPLUS.NS
Share

MedPlus Health Services Limited Stocks

₹ 720.55Last Updated 24.07.2026

Issuer Rating

4/7
Performance

Average

Risk

Limited

Recommendation

Hold

Market Cap

₹ 999.53M

₹ 720.55
Key Takeaways

Risk factor

Strong & resilient to price shocks

Data is available to registered users only
Data is available to registered users only

Profitability factor

Very favourable analyst view

Data is available to registered users only
Data is available to registered users only
Sign up to get free access to key risk and return factors, detailed company valuation, and analyst forecasts
Sign up to access all the key risk and return factors

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis

About

MedPlus Health Services Limited operates primarily as an Indian retailer of pharmaceutical products and diverse general merchandise. Its extensive product catalog includes vital health and wellness items such as prescription medications, vitamins, medical equipment, and diagnostic kits, alongside everyday essentials like toiletries, baby care products, cleaning supplies, and sanitizers. Beyond its retail footprint, the company also offers wholesale cash-and-carry services, comprehensive pathological laboratory testing, and contract manufacturing for its own-brand pharmaceutical goods. By March 31, 2021, MedPlus had established a substantial presence with 1,659 brick-and-mortar stores situated in the Indian states of Karnataka, Tamil Nadu, Telangana, and Andhra Pradesh, complemented by its online store. This Hyderabad-based company was incorporated in 2006.

Company Valuation

Slightly overvalued
3/7

Considering past and projected metrics, the stock is moderately 'expensive' compared to its peers. Specifically, the stock is 'expensive' on P/E, neutral on EV/EBITDA, ov

Data is available to registered users only
Sign up to access detailed valuation

Target Price

Very favourable
7/7

The average target price of MEDPLUS.NS is 1225 and suggests 70% upside potential. Usually, this means a BUY recommendation among investment firms, or a recommendation to

Data is available to registered users only
Sign up to access analyst forecasts

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis

Trending

26.07.2026 21:33

Revolut Valued at $115 Billion and a Record-Breaking Deal in Asia: Key Takeaways on IPOs as of July 26

26.07.2026 15:01

AI Tools to Combat Cognitive Biases: How Investors Can Use Them

25.07.2026 16:01

Small caps last week: New Nasdaq rules, AI hurting Tripadvisor, Archer's rotorcraft

25.07.2026 13:50

Chevron Discussed with the U.S. How to Protect Its Interests in Kazakhstan from the Effects of the War — WSJ

25.07.2026 13:01

The "Three Seas" Risk Zone, Tesla Hit by Expenses, and "Odyssey" — the Driving Force Behind Movie Theaters

X-channel

Buy

Sell

0 more stocks

Company

  • About
  • Contributors
  • Contacts
  • Legal Information

Social media

  • X (Twitter)
  • LinkedIn

Services

  • Stock Screener
  • Guru Portfolios
  • X (Twitter)
  • LinkedIn
Oninvest© 2026